URINE ALBUMIN-TO-CREATININE RATIO AND ESTIMATED GLOMERULAR FILTRATION RATE IN MATCHED GROUPS OF TYPE 2 DIABETES MELLITUS PATIENTS RECEIVING METFORMIN AND METFORMIN-SULFONYLUREA

RANI SAURIASARI; HANIFA ARISTIA; AZIZAHWATI

doi:10.22159/ijap.2020.v12s1.FF056

Authors

RANI SAURIASARI Clinical Pharmacy Division, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia
HANIFA ARISTIA Clinical Pharmacy Division, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia
AZIZAHWATI Clinical Pharmacy Division, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia

DOI:

https://doi.org/10.22159/ijap.2020.v12s1.FF056

Keywords:

Metformin, Sulfonylurea, Estimated glomerular filtration rate, Urine albumin-to-creatinine ratio

Abstract

Objective: Renal disease complications in type 2 diabetes mellitus patients are characterized by progressive urinary albumin excretion and decreased
glomerular filtration. The drugs most commonly prescribed as antidiabetic therapy in Indonesia are metformin and sulfonylurea. It is still unclear
whether the effect of metformin-sulfonylurea on kidney is different from that of metformin monotherapy.
Methods: We compared the effectiveness of metformin monotherapy and metformin-sulfonylurea combination to the urine albumin-to-creatinine
ratio (UACR) and estimated glomerular filtration rate (eGFR) as renal function parameters. Study subjects were patients on either of these drug
regimens for at least 1 year. We collected 88 samples from type 2 diabetes mellitus patients (37 patients on metformin and 51 on metforminsulfonylurea).
The patients fasted for 8 h before urine and blood collection for UACR and eGFR analysis. We measured the eGFR using the chronic
kidney disease epidemiology collaboration (CKD-EPI) equation, serum creatinine, and urine creatinine by colorimetric enzymatic assay, and urine
albumin by immunoturbidimetry.
Results: The eGFR level in the metformin and metformin-sulfonylurea groups was within the normal range, but lower in the metformin group
(79.59±2.81) than in the metformin-sulfonylurea group (87.82±2.82) (p=0.018). In addition, hyperfiltration cases were more frequent in metforminsulfonylurea
group (p=0.029). The UACR in patients taking metformin-sulfonylurea (177.95±60.92) was higher than that in the metformin group
(49.58±14.19) but the difference between them was not significant (p=0.099).
Conclusion: Metformin monotherapy was associated with a lower frequency of hyperfiltration and lower UACR level compared to metforminsulfonylurea
combination.

Downloads

Download data is not yet available.

References

1. Giacco F, Brownlee M. Pathogenesis of microvascular complications.
Textbook of Diabetes. 4th ed. United States: Blackwell Publishing Ltd.;
2010. p. 553-74.
2. Simatupang TA, Wijaya S. Nefropati pada pasien diabetes mellitus.
Dam J Med 2010;9:30-7.
3. Gross J, de Azevedo M, Silveiro S, Canani L, Caramori M,
Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and
treatment. Diab Care 2004;28:164-76.
4. Sauriasari R, Andriany R, Sekar A. Comparison of antioxidative effect
of metformin and combination of metformin-sulfonylurea in type 2
diabetes mellitus patients. J Young Pharm 2017;9:s39-42.
5. Nasri H, Baradaran A, Reza AM, Mardani S, Momeni A, Rafieian-
Kopaei M. Bright renoprotective properties of metformin beyond blood
glucose regulatory effects. Iran J Kidney Dis 2013;7:423-8.
6. Sauriasari R, Andrajati R, Azizahwati, Dharmeizar, Saputri DA,
Muris RU, et al. Marker of lipid peroxidation related to diabetic
nephropathy in Indonesian type 2 diabetes mellitus patients. Diabetes
Res Clin Pract 2015;108:193-200.
7. Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, et al.
Kidney function decline in metformin versus sulfonylurea initiators:
Assessment of time-dependent contribution of weight, blood pressure,
and glycemic control. Pharmacoepidemiol Drug Saf 2013;22:623-31.
8. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of
amputation, blindness, severe kidney failure, hyperglycaemia,
and hypoglycaemia: Open cohort study in primary care. BMJ
2016;352:i1450.
9. World Health Organization. Global Database on Body Mass
Index. Available from: http://www.apps.who.int/bmi/index.
jsp?introPage=intro_3.html. [Last accessed on 2019 July 20].
10. Cheung B, Li C. Diabetes and hypertension: Is there a common
metabolic pathway? Curr Atherscler Rep 2012;14:160-6.
11. Hsu CC, Chang HY, Huang MC, Hwang SJ, Yang YC, Lee YS, et al.
HbA1c variability is associated with microalbuminuria development
in type 2 diabetes: A 7-year prospective cohort study. Diabetologia
2012;55:3163-72.
12. American Diabetes Association. Standards of Medical Care in
Diabetes-2017. Available from: http://www.care.diabetesjournals.org/
content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_40_S1_
final.pdf. [Last accessed on 2019 July 20].
13. Sauriasari R, Mahani R, Sekar A. Urinary hydrogen peroxide and renal
function parameter of type 2 diabetes mellitus patients consuming
metformin and metformin-sulfonylurea. J Young Pharm 2017;9:s5-8.
14. Kumar DA, Arivazhagan R, Sudhandiran G, Sangeetha R,
Swaminathan S. The effect of metformin monotherapy on biochemical
parameters associated with diabetes mellitus, kidney, cardiac, liver,
thyroid, and reproductive organ functions in pre-and post-menopause
women with type 2 diabetes mellitus. Asian J Pharm Clin Res
2018;11:84-91.
15. Geetha P, Shanmugasundaram P. Correlation of microalbuminuria with
age, duration, glycated hemoglobin, blood sugar levels, blood pressure
and renal parameters of type 2 diabetes patients. Asian J Pharm Clin
Res 2017;10:397-400.
16. Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P,
Gibson JM, et al. The unrecognized prevalence of chronic kidney
disease in diabetes. Nephrol Dial Transplant 2006;21:88-92.